Menu Search
Equities

Paion AG

PA8:MUN

Paion AG

Actions
  • Price (EUR)0.031
  • Today's Change0.001 / 3.33%
  • Shares traded30.00
  • 1 Year change-99.33%
  • Beta--
Data delayed at least 15 minutes, as of May 23 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.

  • Revenue in EUR (TTM)--
  • Net income in EUR--
  • Incorporated2004
  • Employees64.00
  • Location
    Paion AGHeussstrasse 25AACHEN 52078GermanyDEU
  • Phone+49 24144530
  • Fax+49 2 414453100
  • Websitehttps://www.paion.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.